Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Molecular Profiling and Targeted Therapy for Advanced Lung and Thymic Cancers
NCT01306045Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2011
- Primary completion
- Feb 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib, selumetinib, MK-2206, lapatinib, sunitinib in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), thymus cancer, sponsored by National Cancer Institute. Started Feb 2011; status: completed.
02
Drugs
erlotinibselumetinibMK-2206lapatinibsunitinib
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)thymus cancer
Beyond the preview
Go deeper on NCT01306045.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01306045.